Apogee Net Working Capital from 2010 to 2025

APGE Stock   40.14  0.25  0.63%   
Apogee Therapeutics,'s Net Working Capital is increasing over the years with slightly volatile fluctuation. Net Working Capital is expected to dwindle to about 374.4 M. During the period from 2010 to 2025 Apogee Therapeutics, Net Working Capital annual values regression line had geometric mean of  173,613,886 and mean square error of 7915.8 T. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
501.2 M
Current Value
374.4 M
Quarterly Volatility
114.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Apogee Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apogee Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 36.5 M, Interest Income of 36.5 M or Depreciation And Amortization of 7.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.66. Apogee financial statements analysis is a perfect complement when working with Apogee Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Apogee Therapeutics, Correlation against competitors.

Latest Apogee Therapeutics,'s Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Apogee Therapeutics, Common over the last few years. It is Apogee Therapeutics,'s Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apogee Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Apogee Net Working Capital Regression Statistics

Arithmetic Mean193,773,415
Geometric Mean173,613,886
Coefficient Of Variation58.95
Mean Deviation84,009,924
Median142,075,000
Standard Deviation114,232,684
Sample Variance13049.1T
Range359.1M
R-Value0.66
Mean Square Error7915.8T
R-Squared0.43
Significance0.01
Slope15,803,470
Total Sum of Squares195736.6T

Apogee Net Working Capital History

2025374.4 M
2024501.2 M
2023377.9 M

About Apogee Therapeutics, Financial Statements

Apogee Therapeutics, stakeholders use historical fundamental indicators, such as Apogee Therapeutics,'s Net Working Capital, to determine how well the company is positioned to perform in the future. Although Apogee Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Apogee Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Apogee Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Apogee Therapeutics, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital501.2 M374.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Apogee Therapeutics, is a strong investment it is important to analyze Apogee Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics,'s future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports:
Check out the analysis of Apogee Therapeutics, Correlation against competitors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apogee Therapeutics,. If investors know Apogee will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apogee Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.30)
Return On Assets
(0.23)
Return On Equity
(0.33)
The market value of Apogee Therapeutics, is measured differently than its book value, which is the value of Apogee that is recorded on the company's balance sheet. Investors also form their own opinion of Apogee Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Apogee Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apogee Therapeutics,'s market value can be influenced by many factors that don't directly affect Apogee Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apogee Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Apogee Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apogee Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.